Ruud Oerlemans

1.5k total citations
23 papers, 1.2k citations indexed

About

Ruud Oerlemans is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Ruud Oerlemans has authored 23 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 8 papers in Molecular Biology and 8 papers in Hematology. Recurrent topics in Ruud Oerlemans's work include Drug Transport and Resistance Mechanisms (8 papers), Rheumatoid Arthritis Research and Therapies (6 papers) and Multiple Myeloma Research and Treatments (5 papers). Ruud Oerlemans is often cited by papers focused on Drug Transport and Resistance Mechanisms (8 papers), Rheumatoid Arthritis Research and Therapies (6 papers) and Multiple Myeloma Research and Treatments (5 papers). Ruud Oerlemans collaborates with scholars based in Netherlands, Israel and United States. Ruud Oerlemans's co-authors include Gerrit Jansen, Rik J. Scheper, Ben A. C. Dijkmans, Joost W van der Heijden, George L. Scheffer, Yehuda G. Assaraf, Willem F. Lems, Godefridus J. Peters, Jacqueline Cloos and Gertjan J.L. Kaspers and has published in prestigious journals such as Blood, Journal of Pharmacology and Experimental Therapeutics and Annals of the Rheumatic Diseases.

In The Last Decade

Ruud Oerlemans

22 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ruud Oerlemans Netherlands	13	583	445	305	153	145	23	1.2k
Toshihiro Fukushima Japan	20	299 0.5×	382 0.9×	246 0.8×	229 1.5×	157 1.1×	77	1.1k
Miki Nishimura Japan	18	422 0.7×	264 0.6×	463 1.5×	34 0.2×	122 0.8×	49	1.1k
Shrikanta Chattopadhyay United States	15	580 1.0×	288 0.6×	225 0.7×	496 3.2×	114 0.8×	25	1.5k
Kourosh Lotfi Sweden	18	400 0.7×	264 0.6×	383 1.3×	71 0.5×	108 0.7×	54	968
Ilan Ifergan Israel	18	390 0.7×	397 0.9×	86 0.3×	251 1.6×	212 1.5×	20	1.1k
Hiroyuki Hamada Japan	10	447 0.8×	563 1.3×	94 0.3×	61 0.4×	44 0.3×	37	980
Jan Sjöberg Sweden	21	383 0.7×	452 1.0×	201 0.7×	104 0.7×	417 2.9×	45	1.4k
Hongsheng Zhou China	20	576 1.0×	314 0.7×	751 2.5×	76 0.5×	219 1.5×	127	1.6k
Ebrahim Sakhinia Iran	22	681 1.2×	266 0.6×	167 0.5×	121 0.8×	184 1.3×	73	1.3k
Luke P. Akard United States	21	294 0.5×	403 0.9×	691 2.3×	225 1.5×	157 1.1×	78	1.3k

Countries citing papers authored by Ruud Oerlemans

Since Specialization

Citations

This map shows the geographic impact of Ruud Oerlemans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruud Oerlemans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruud Oerlemans more than expected).

Fields of papers citing papers by Ruud Oerlemans

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruud Oerlemans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruud Oerlemans. The network helps show where Ruud Oerlemans may publish in the future.

Co-authorship network of co-authors of Ruud Oerlemans

This figure shows the co-authorship network connecting the top 25 collaborators of Ruud Oerlemans. A scholar is included among the top collaborators of Ruud Oerlemans based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruud Oerlemans. Ruud Oerlemans is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Oerlemans, Ruud, Celia R. Berkers, Yehuda G. Assaraf, et al.. (2018). Proteasome inhibition and mechanism of resistance to a synthetic, library-based hexapeptide. Investigational New Drugs. 36(5). 797–809. 6 indexed citations

Smolen, Josef S, Nael M. Mostafa, Xin Huang, et al.. (2018). THU0185 The value of adalimumab trough levels and clinical assessments in predicting clinical response in patients with established rheumatoid arthritis and an inadequate response to methotrexate. Annals of the Rheumatic Diseases. 77. 311–311. 2 indexed citations

Gerards, A., et al.. (2013). Methotrexate analogues display enhanced inhibition of TNF-α production in whole blood from RA patients. Scandinavian Journal of Rheumatology. 43(1). 9–16. 12 indexed citations

Verbrugge, Sue Ellen, Yehuda G. Assaraf, Ben A. C. Dijkmans, et al.. (2012). Inactivating PSMB5 Mutations and P-Glycoprotein (Multidrug Resistance-Associated Protein/ATP-Binding Cassette B1) Mediate Resistance to Proteasome Inhibitors: Ex Vivo Efficacy of (Immuno)Proteasome Inhibitors in Mononuclear Blood Cells from Patients with Rheumatoid Arthritis. Journal of Pharmacology and Experimental Therapeutics. 341(1). 174–182. 87 indexed citations

Dijk, A. van, Benno A. Naaijkens, Wouter J.F.M. Jurgens, et al.. (2012). The multidrug resistance protein breast cancer resistance protein (BCRP) protects adipose-derived stem cells against ischemic damage. Cell Biology and Toxicology. 28(5). 303–315. 10 indexed citations

Kooij, Gijs, Jack van Horssen, Elizabeth C. M. de Lange, et al.. (2009). T lymphocytes impair P-glycoprotein function during neuroinflammation. Journal of Autoimmunity. 34(4). 416–425. 48 indexed citations

Heijden, Joost W van der, Ruud Oerlemans, Paul P. Tak, et al.. (2009). Involvement of breast cancer resistance protein expression on rheumatoid arthritis synovial tissue macrophages in resistance to methotrexate and leflunomide. Arthritis & Rheumatism. 60(3). 669–677. 54 indexed citations

Heijden, Joost W van der, Ruud Oerlemans, Willem F. Lems, et al.. (2009). The proteasome inhibitor bortezomib inhibits the release of NFkappaB-inducible cytokines and induces apoptosis of activated T cells from rheumatoid arthritis patients.. PubMed. 27(1). 92–8. 49 indexed citations

Heijden, Joost W van der, Ruud Oerlemans, Ben A. C. Dijkmans, et al.. (2008). Folate receptor β as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients. Arthritis & Rheumatism. 60(1). 12–21. 127 indexed citations

10.

Ven, Rieneke van de, George L. Scheffer, Anneke W. Reurs, et al.. (2008). A role for multidrug resistance protein 4 (MRP4; ABCC4) in human dendritic cell migration. Blood. 112(6). 2353–2359. 51 indexed citations

11.

Franke, N., Ruud Oerlemans, Ina van Zantwijk, et al.. (2008). Acquisition of Mutations in the PSMB5 Gene during Chronic Exposure of Human Acute Lymphoblastic Leukemia CCRF-CEM Cells to the Proteasome Inhibitor Bortezomib. Blood. 112(11). 2642–2642.

12.

Oerlemans, Ruud, N. Franke, Yehuda G. Assaraf, et al.. (2008). Molecular basis of bortezomib resistance: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood. 112(6). 2489–2499. 357 indexed citations

13.

Oerlemans, Ruud, B.A.C. Dijkmans, Yehuda G. Assaraf, et al.. (2007). Sulfasalazine sensitises human monocytic/macrophage cells for glucocorticoids by upregulation of glucocorticoid receptor α and glucocorticoid induced apoptosis. Annals of the Rheumatic Diseases. 66(10). 1289–1295. 12 indexed citations

14.

Franke, N., Ruud Oerlemans, Sonja Zweegman, et al.. (2007). Molecular Mechanisms of Bortezomib Resistance in Acute Lymphoblastic Leukemia Cells in Comparison with Multiple Myeloma Cells.. Blood. 110(11). 3469–3469. 2 indexed citations

15.

Oerlemans, Ruud, Ben A. C. Dijkmans, Gertjan J.L. Kaspers, et al.. (2006). Acquired resistance to chloroquine in human CEM T cells is mediated by multidrug resistance–associated protein 1 and provokes high levels of cross‐resistance to glucocorticoids. Arthritis & Rheumatism. 54(2). 557–568. 31 indexed citations

16.

Luurtsema, Gert, Mark Lubberink, Tessa M. Bosch, et al.. (2006). Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[11C]verapamil and positron emission tomography. Clinical Pharmacology & Therapeutics. 79(6). 540–548. 141 indexed citations

17.

Gerards, A., Ruud Oerlemans, RJ Scheper, et al.. (2005). Inhibition of tumour necrosis factor alpha production by activated T cells of rheumatoid arthritis patients by novel anti-folate drugs: an ex vivo pilot study. Arthritis Research. 7(Suppl 1). P84–P84. 2 indexed citations

18.

Oerlemans, Ruud, et al.. (2005). Differential expression of multidrug resistance-related proteins on monocyte-derived macrophages from rheumatoid arthritis patients. Arthritis Research. 7(Suppl 1). P83–P83. 3 indexed citations

19.

Jansen, Gerrit, Ruud Oerlemans, Willem F. Lems, et al.. (2004). Sulfasalazine is a potent inhibitor of the reduced folate carrier: Implications for combination therapies with methotrexate in rheumatoid arthritis. Arthritis & Rheumatism. 50(7). 2130–2139. 56 indexed citations

20.

Bruin, Michiel de, Godefridus J. Peters, Ruud Oerlemans, et al.. (2004). Sulfasalazine Down-Regulates the Expression of the Angiogenic Factors Platelet-Derived Endothelial Cell Growth Factor/Thymidine Phosphorylase and Interleukin-8 in Human Monocytic-Macrophage THP1 and U937 Cells. Molecular Pharmacology. 66(4). 1054–1060. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact